IMS Health, Inc. (RX)
The Company provides critical business intelligence, including information, analytics and consulting services to the pharmaceutical and healthcare industries worldwide.
Recs
Paramnesia1930
(98.20)
Submitted: 11/3/2009 8:47:48 AM :
Start Price:
$16.53
RX Score:
-23.71
More than 9% above its 50-Day Moving Average.
Recs
germanjuggler
(< 20)
Submitted: 10/19/2009 11:43:30 PM :
Start Price:
$17.45
RX Score:
+22.87
quick money but be careful.
Recs
ChumpChangeNC
(39.58)
Submitted: 10/19/2009 6:14:20 PM :
Start Price:
$15.17
RX Score:
+39.22
According to CNBC, IMS Health is in "advanced talks" about a take-over from private equity firms. The word on the street is that they have been offered around a 30% premium for the company, thus the jump this afternoon late in trading and in extended hours. I don't know what to do right now because I own some of this stock but it looks good either way for anyone who owns shares.
Recs
Gordon024
(29.55)
Submitted: 10/8/2009 9:56:37 AM :
Start Price:
$15.11
RX Score:
+38.45
Lots of growth potential, should steadily rise year over year for the next several years.
Recs
mmacioci
(74.19)
Submitted: 10/7/2009 8:22:23 AM :
Start Price:
$14.79
RX Score:
+40.43
hidden gem and early buffet
Recs
tringuyen6
(59.80)
Submitted: 9/30/2009 10:51:58 AM :
Start Price:
$15.11
RX Score:
+36.92
HG porfolio. Will do great after the health care reform passes
Recs
jmpreiks
(91.29)
Submitted: 9/27/2009 9:56:16 AM :
Start Price:
$15.12
RX Score:
+36.87
This stock is undervalued and should continue to do well after health care reform if cost cutting is truly emphasized.
Recs
stan8331
(96.68)
Submitted: 9/23/2009 5:55:00 PM :
Start Price:
$15.24
RX Score:
+37.29
Low P/E, no debt, high ROIC, nice moat, and even paying a small dividend (that's likely to be growing). Oh yeah, there's also this massive generation of baby boomers who are getting older and will be consuming more and more medications. The odds of many states outlawing this sort of data exchange seems very remote to me. I think I'll put some real-world money on this one...
Recs
wtcrane1
(93.31)
Submitted: 9/18/2009 3:40:20 PM :
Start Price:
$15.45
RX Score:
+35.95
great moat, undervalued
Recs
TomFoolNC
(97.39)
Submitted: 9/18/2009 2:06:10 PM :
Start Price:
$15.42
RX Score:
+35.15
scripts data
Recs
latimerburned
(79.08)
Submitted: 9/15/2009 4:39:06 PM :
Start Price:
$14.94
RX Score:
+39.31
A smallish heath care stock to watch. The video valuation for HG subscribers has intrigued me.
Recs
KempInTheWoods
(75.86)
Submitted: 9/14/2009 10:50:03 AM :
Start Price:
$14.69
RX Score:
+40.36
Currently undervalued. Wide moat: information on drug sales from wide variety of sources. Pharma companies have temporarily cut back on IMS's services, but longer term will have to come back to them.
Recs
orizonalpha
(94.20)
Submitted: 9/13/2009 12:52:04 AM :
Start Price:
$14.88
RX Score:
+37.66
This will rebound when the uncertainty around health care reform passes.
Recs
Seansonfire
(97.47)
Submitted: 8/26/2009 1:33:14 PM :
Start Price:
$13.97
RX Score:
+46.23
Great area for growth as the Baby Boomers start to get older and retire. If any change in the US national healthcare is made, RX would profit from providing consultanting services that would be needed to make adjustments to the new healthcare system.
PE ratio is pretty wonderful right now as well.
Recs
GrahamJervis
(54.80)
Submitted: 8/19/2009 3:49:16 PM :
Start Price:
$13.03
RX Score:
+53.76
ample free cash flow, buying back stock and reducing debt. also the company has a wide moat.
Recs
fdude71
(93.80)
Submitted: 7/23/2009 10:45:04 PM :
Start Price:
$11.72
RX Score:
+69.15
End July 09
PE of 6.11
CAPS 5 STARS
Negative shareholder equity (requires very little tangible capital to operate)
Generates LOTS of free cash flow
Sells dirt cheap, for about six times free cash flow
It will be hard to find a better time to get in on this one
On top of that it pays nearly 1% at this price... and Payout ratio is 6... I'd rather put my money there than in a CD!
Double the money in 1 year...
Recs
ena1902
(< 20)
Submitted: 6/16/2009 11:47:25 AM :
Start Price:
$13.25
RX Score:
+41.09
with some form of medical insurance in the wind the pharmecutical cos will want all info available in U.S. This co also operates in world markets and competition will drive demand for its services.
Recs
FoolSolo
(90.17)
Submitted: 6/16/2009 7:34:05 AM :
Start Price:
$13.45
RX Score:
+40.16
RX has good technicals, decent financials and a respectable track record of zero debt, good cash flow, increasing sales and earnings. They seem to be an investor friendly company. Although lowering outlook, they didn't deserve to be taken out to the woodshed and shot. I think there is value here.
Recs
SuperCharge
(98.60)
Submitted: 6/5/2009 1:35:48 PM :
Start Price:
$11.94
RX Score:
+62.26
Slowing growth in the teeter-tottering market, but RX has a very low P/E at 5.8 if you assume they'll competitively keep tabs for big pharma in the future. As I believe in an booming bio-pharma industry, RX looks like a good risk/reward.
Recs
TokyoIrish
(88.60)
Submitted: 6/3/2009 5:07:06 AM :
Start Price:
$12.11
RX Score:
+58.83
Consistently high returns on capital. Undervalued.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 29 1 2 Next »